Dual serotonin and noradrenaline uptake inhibitor class of antidepressants — Potential for greater efficacy or just hype?
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Preclinical and clinical studies support the rationale that development of single molecules, which would promote serotonergic and noradrenergic neurotransmission by inhibiting simultaneously the uptake of both monoamines, would potentially result in improved antidepressant drugs. Currently, the dual inhibitors of serotonin and noradrenaline uptake are venlafaxine, milnacipran and duloxetine. Based on the preclinical studies, the three drugs do show properties of inhibiting uptake of both monoamines in vitro and in vivo in the following order of decreasing potency: duloxetine, venlafaxine and milnacipran, and all exhibit low affinity at neuronal receptors of neurotransmitters, suggesting low side-effect potential. In double-blind, controlled studies, venlafaxine and milnacipran were repeatedly shown to be as efficacious as tricyclic antidepressant drugs in treating major depressive disorder, while one double-blind, placebo-controlled trial showed the antidepressant efficacy of duloxetine. Specifically designed comparative trials of dual uptake inhibitors against the other agents are needed to establish whether the dual uptake inhibitors show improvement in efficacy, rate of responders, antidepressive effects and/or remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374
Delgado, P. L. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110025005 · Cited by 289
Miller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192
Haddjeri, N., De Montigny, C., & Blier, P. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700968 · Cited by 164
Redrobe, J. P., Bourin, M., Colombel, M. C., & Baker, G. B. (1998) · Psychopharmacology · doi:10.1007/s002130050638 · Cited by 163
Löscher, W., Annies, R., & Hönack, D. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90258-u · Cited by 150
Kihara, T., & Ikeda, M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24303-8 · Cited by 123
Cited by
Duloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858
Antidepressants in the Treatment of Neuropathic Pain
Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_96696601.x · Cited by 624
Raskin, J., Pritchett, Y. L., Wang, F., D'Souza, D. N., Waninger, A. L., Iyengar, S., & Wernicke, J. F. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 532
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Metadata
- Authors
- Wong, D. T., & Bymaster, F. P.
- Venue
- Progress in Drug Research
- Publisher
- Birkhäuser Basel
- Published
- 2002
- Volume
- 58
- Pages
- 169-222
- OpenAlex
- W51209413
- Cited by
- 112
- References
- 11
- FWCI
- 35.00
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.